Promising Trial Results Could Propel Galectin Therapeutics
AI Prediction of Galectin Therapeutics Inc. (GALT)
Galectin Therapeutics (GALT), a clinical-stage biopharmaceutical company, is focusing on developing therapies for fibrotic disease and cancer. The company's lead candidate, belapectin, shows potential in reversing liver fibrosis and treating NASH cirrhosis. With several clinical trials active and upcoming catalysts likely related to trial outcomes, Galectin Therapeutics presents a speculative but potentially rewarding investment opportunity as it progresses through key clinical milestones.
GALT Report Information
Prediction Date2025-07-03
Close @ Prediction$2.18
Mkt Cap452m
IPO DateN/a
AI-derived Information
Recent News for GALT
- Aug 14, 8:00 am — Galectin Therapeutics Reports June 30, 2026 Financial Results and Provides Business Update (GlobeNewswire RSS)
- Aug 14, 7:55 am — GALT files 8-K with clinical-trial language (ScanScor Filing Bot)
- Aug 14, 7:51 am — GALT SEC filing points to financing activity (ScanScor Filing Bot)
- Aug 4, 8:00 am — Galectin Therapeutics Announces Conversion of $105.8 Million in Debt to Equity, Significantly Strengthening Balance Sheet (GlobeNewswire RSS)
- Jun 23, 1:47 pm — GALT Stock Surges 22% On Track For Best Day In Over A Year After FDA Clears Path For Late-Stage Belapectin Trial (Stocktwits)
- Jun 23, 8:00 am — Galectin Therapeutics Announces Positive Type C Meeting with the FDA for Belapectin in Patients with MASH Cirrhosis and Portal Hypertension (GlobeNewswire RSS)
- May 27, 8:00 am — Galectin Therapeutics Presents New EASL 2026 Oral and Poster Analyses Demonstrating Belapectin’s Potential to Modify Disease Progression in Advanced MASH Cirrhosis (GlobeNewswire RSS)
- May 15, 8:00 am — Galectin Therapeutics Reports March 31, 2026 Financial Results and Provides Business Update (GlobeNewswire)
- May 11, 8:00 am — Galectin Therapeutics Announces Publication of NAVIGATE Phase 2b Trial Results for Belapectin in the Journal of Hepatology (GlobeNewswire)
- Mar 31, 8:00 am — Galectin Therapeutics Reports 2025 Financial Results and Provides Business Update (GlobeNewswire)
- Mar 17, 8:00 am — Galectin Therapeutics Strengthens Board of Directors with Appointment of Henry Brem, M.D. (GlobeNewswire)
- Feb 26, 4:05 pm — Galectin Therapeutics to Host Virtual KOL Event to Discuss Belapectin Development Program for Treatment of Metabolic Dysfunction-Associated Steatohepatitis (MASH) Cirrhosis and Portal Hypertension, on March 10, 2026 at 12:00 PM ET (GlobeNewswire)
Welcome to ScanScor. What you're reading is no ordinary summary -- it's the result of a carefully-crafted interactive session with OpenAI's most advanced models crafted from news, trial details, and financial data. This report attempts to maximize the potential for OpenAI's smartest GPT-based analysis engine, guided by tightly structured prompts to expose the forces behind today's market movers and to predict the future.
Disclaimer: This report is for informational purposes only. It does not constitute financial advice. Always do your own research before making any investment.
Galectin Therapeutics (GALT) Update
Galectin has already more than doubled since our July 3 prediction at $2.18, now trading around $4.70–$4.80. The catalyst was results from the NAVIGATE Phase 3 trial of belapectin in NASH cirrhosis. While the trial missed its primary endpoint in the full population, the 2 mg/kg dose showed a significant benefit in reducing new varices among patients who completed the study, with favorable liver stiffness trends as well.
This partial win keeps the $6 target in sight, though the path is less certain given the mixed data. Near-term moves will depend on longer-term follow-up data, regulatory guidance, and possible partnerships.
Bottom line: The stock has delivered strong gains since our call, but future upside comes with higher risk now that trial results are public.